Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Chimerix’s broad spectrum antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release.
Chimerix Awarded BARDA Contract for Advanced Development of CMX001 as Medical Countermeasure Against Smallpox
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Financing Reflects Significant Clinical Progress and Positive Data in Lead Programs
RESEARCH TRIANGLE PARK, NC, February 14, 2011 – Chimerix, Inc., a pharmaceutical company developing orally- available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Chimerix, Inc., a pharmaceutical company developing orally- available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
Marina Biotech and The Debiopharm Group Partner to Develop and Commercialize RNAi-Based Therapies for the Treatment of Bladder Cancer
The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development group of companies with a main focus in oncology and serious medical conditions, and Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that they entered into an exclusive agreement concerning the development and commercialization of Marina Biotech's pre-clinical program in bladder cancer.
Researchers From Case Western Reserve and Athersys Publish Landmark Study Showing Regenerative Benefit of MultiStem Therapy After Spinal Cord Injury
Case Western Reserve University School of Medicine and Athersys, Inc. (Nasdaq:ATHX) announced a joint scientific study on spinal cord injury will be published today in the January issue of The Journal of Neuroscience. The study, by leading researchers from the Department of Neurosciences at the School
of Medicine and scientists at Athersys, presents data supporting the potential therapeutic benefit of Athersys' MultiStem® program for spinal cord injury. Researchers observed that administration of Multipotent Adult Progenitor Cells (MAPC) following spinal cord injury in rodent models prevented the retraction of neurons, a process referred to as "axonal dieback," reduced inflammation in the region of injury, and also promoted the regrowth of neurons.
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
Study Meets Co-Primary Endpoints: Overall Survival and Progression-Free Survival Benefit
Plexxikon's U.S. Patent for PLX4032 Issues
Berkeley, CA — January 18, 2011 - Plexxikon Inc. today announced positive data from an interim analysis of the BRIM3 trial, a large multi‐ center Phase 3 clinical study of PLX4032 (RG7204) in patients with previously untreated metastatic melanoma with the BRAF mutation. Patients treated with PLX4032 had an improved overall survival (OS) compared to patients treated with dacarbazine, the current standard of care. In addition, these patientslived longer on average without their disease getting worse, as measured by progression‐free survival (PFS). PLX4032 is an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation.
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
Plexxikon Inc. today announced positive data from an interim analysis of the BRIM3 trial, a large multi‐ center Phase 3 clinical study of PLX4032 (RG7204) in patients with previously untreated metastatic melanoma with the BRAF mutation. Patients treated with PLX4032 had an improved overall survival (OS) compared to patients treated with dacarbazine, the current standard of care. In addition, these patientslived longer on average without their disease getting worse, as measured by progression‐free survival (PFS). PLX4032 is an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation.
TYRX, Inc. raises $20 million in private financing
Proceeds will Support Continued Commercialization of the AIGISRx® Antibacterial Envelope and Development of Next Generation Products
Monmouth Junction, NJ (December 8, 2010) – TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections associated with implantable pacemakers and defibrillators, announced today that it has raised $20 million in venture capital funding. The funding was led by new investor, HLM Venture Partners along with previous investors Clarus Ventures and Pappas Ventures. The financing round also included $4 million in debt financing from Comerica Bank. In connection with the financing, Edward L. Cahill, Managing Partner, HLM Venture Partners, will join TYRX’s Board of Directors.
TYRX, Inc. raises $20 million in private financing
TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections associated with implantable pacemakers and defibrillators, announced today that it has raised $20 million in venture capital funding. The funding was led by new investor, HLM Venture Partners along with previous investors Clarus Ventures and Pappas Ventures. The financing round also included $4 million in debt financing from Comerica Bank. In connection with the financing, Edward L. Cahill, Managing Partner, HLM Venture Partners, will join TYRX’s Board of Directors.
Genstruct, Inc. changes name to Selventa as company launches re-branding effort
SelventaTM, which evolved from Genstruct®, Inc. today announced that it has changed its name and launched a re-branded website as part of an initiative to provide innovative solutions for its client partners. The company’s core strengths embrace a customer-focused approach that leverages existing patient data and innovative analytics to help pharmaceutical and biotechnology partners accelerate development and clarify decisions on therapeutics and diagnostics.
